Role of granulocyte-macrophage colony-stimulating factor as adjuvant therapy for fungal infection in patients with cancer.
A pilot study was conducted to evaluate the role of granulocyte-macrophage colony-stimulating factor (GM-CSF) as adjuvant therapy for fungal infections in patients with cancer. GM-CSF was added to amphotericin B in the treatment of cancer patients with proven major-organ or disseminated fungal infection. The dose of GM-CSF ranged from 100 to 750 micrograms/(m2.d). Of eight evaluable patients, six had a neutrophil response to GM-CSF. Four of these patients were completely cured of the fungal infection, and two had a partial response. However, a capillary-leak syndrome developed in three patients, an adverse effect suggesting that the dose of GM-CSF was excessive.
Bodey
G P
GP
University of Texas MD Anderson Cancer Center, Houston 77030.
Anaissie
E
E
Gutterman
J
J
Vadhan-Raj
S
S
D000328:Adult; D000368:Aged; D000666:Amphotericin B / Q000627:therapeutic use; D002199:Capillary Permeability / Q000187:drug effects; D005260:Female; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D016867:Immunocompromised Host; D007958:Leukocyte Count; D008297:Male; D008875:Middle Aged; D009181:Mycoses / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology; D009369:Neoplasms / Q000150:complications* / Q000276:immunology; D009504:Neutrophils / Q000187:drug effects; D010865:Pilot Projects; D011994:Recombinant Proteins / Q000009:adverse effects / Q000627:therapeutic use; D013577:Syndrome
D011994:Recombinant Proteins; D000666:Amphotericin B; D016178:Granulocyte-Macrophage Colony-Stimulating Factor